From CNBC: 2024-06-07 18:21:42

The FDA expanded GSK’s RSV vaccine, Arexvy, approval to adults ages 50-59 at high risk of severe illness. RSV causes hospitalizations and deaths among seniors annually; now younger adults with chronic conditions can benefit. GSK aims to bring in over £3 billion annually as it competes in the RSV market.



Read more at CNBC: FDA approves GSK RSV vaccine for adults 50 to 59